This inventor holds 27 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 6 EPO patents, primarily in Synthetic Peptide Amides. Top assignees: Cara Therapeutics, Inc., Ferring B.v., Cera Therapeutics, Inc.. Active years: 1993-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- La Jolla, CA (US) (1993 - 1999)
- San Diego, CA (US) (2008 - 2021)
Company Filing History:
17 out of 31 
8 out of 209 
1 out of 1 
Years Active: 1993-2021
Areas of Expertise:
Title: Claudio Daniel Schteingart: A Leader in Synthetic Peptide Research
Introduction
Claudio Daniel Schteingart, based in San Diego, CA, is a prominent inventor known for his groundbreaking work in the field of synthetic peptides. With a remarkable portfolio of 27 patents, Schteingart has made significant contributions to medical science, particularly in the development of innovative treatments for pain and inflammation.
Latest Patents
Among his latest inventions, Schteingart has focused on synthetic peptide amides and dimers, which are designed as ligands for the kappa opioid receptor. His patents detail the unique properties of these compounds, including their potential as agonists that exhibit low PCYP inhibition and minimal brain penetration. These advancements are particularly vital for developing therapies aimed at alleviating pain and inflammation related to various diseases and conditions.
Career Highlights
Schteingart has had an influential career, collaborating with notable companies such as Cara Therapeutics, Inc. and Ferring B.V. His experience in these organizations has allowed him to push the boundaries of peptide research and apply his findings in practical, therapeutic contexts.
Collaborations
Throughout his career, Schteingart has worked alongside talented professionals, including Guangcheng Jiang and Javier Sueiras-Diaz. These collaborations have fortified his research efforts and contributed to the successful development of his innovative peptide products.
Conclusion
With a strong commitment to advancing medical treatments and a solid record of patents, Claudio Daniel Schteingart continues to be a key figure in the realm of synthetic peptides. His ongoing work promises to pave the way for new therapeutic options, improving the quality of life for many individuals suffering from pain and inflammation-related conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile